ClinicalTrials.gg

Program

Foralumab Nasal

Its studies are mostly in Amyotrophic Lateral Sclerosis · Multiple System Atrophy, led by Tiziana Life Sciences.

Furthest: phase 2, since Mar 6, 20253 company-led studies, 2 open or runningNext primary completion: Apr 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tiziana Life Sciences32 open or runningphase 2since Mar 6, 2025Mar 6, 2025Apr 1, 2027phase 2 · NCT06868628

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2025First study: phase 2 study in Multiple System AtrophyFirst studyNCT06868628 · 5 planned · United States
  2. Mar 11, 2025Phase 1 study in SafetyNCT06879067 · 27 enrolled · United States
  3. Jun 30, 2026Phase 2 study in Amyotrophic Lateral SclerosisNCT07688239 · 44 planned · United States

Ahead

  1. Apr 1, 2027Primary completion: phase 2 study in Multiple System AtrophyNCT06868628
  2. Jul 2027Primary completion: phase 2 study in Amyotrophic Lateral SclerosisNCT07688239

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07688239Amyotrophic Lateral Sclerosis · United States2By invitationJul 202744
NCT06879067Safety · United States1CompletedJul 23, 201927
NCT06868628Multiple System Atrophy · United States2RecruitingApr 1, 20275

How it is read

Names in the registry

  • “Foralumab Nasal”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.